

EURAZEO INVESTS IN CRANIAL TECHNOLOGIES, THE MARKET LEADER IN TREATING INFANT PLAGIOCEPHALY

New York, 26 January 2022

Eurazeo, through its Mid-Large Buyout strategy, today announced it has acquired a majority stake in Cranial Technologies, the market leader in treating infant plagiocephaly (commonly known as “Flat Head Syndrome”). Eurazeo is investing over \$200 million alongside an equity rollover from the existing management team.

Founded in 1986, Cranial Technologies is the leading treatment provider and manufacturer of helmets used for treating infants with various forms of plagiocephaly, brachycephaly and scaphocephaly. Plagiocephaly is a common condition that affects nearly half of all babies born each year. To date, Cranial Technologies has cared for over 300,000 babies using its FDA-approved DOC Band® cranial orthotic. The Company delivers its helmets through 80 locations based in the US, which it operates to treat patients directly, in addition to six licensed clinics internationally.

Eurazeo’s investment will support Cranial Technologies’ expansion across the US and other key international markets by increasing awareness and expanding its clinical locations, in addition to extending its product offerings into complementary business lines. Its strong pediatrician referral network and custom manufacturing capabilities are solid strategic assets for Cranial Technologies’ development.

Marc Frappier, Member of the Executive Board, Managing Partner of Mid-Large Buyout, commented:

“We are delighted to announce the acquisition of Cranial Technologies, the fifth investment for Eurazeo’s Mid-Large buyout strategy in the US. We are proud to be the partner of choice for mid-sized companies with strong development ambitions. With Eurazeo, Cranial Technologies will benefit from a deep healthcare expertise, a team of committed experts, a global network and financial resources.”

Eric Sondag, Managing Director, Eurazeo, Mid-Large Buyout stated:

“Cranial Technologies is an industry leader that has pioneered a solution for a common condition for infants, ensuring they reach their early development milestones successfully. Debbie and her team have built a business centered on delivering superior outcomes for patients and their families, which is evident in their customer satisfaction metrics and loyalty with prescribing physicians. We’re pleased to partner with Debbie and the rest of the management team to raise awareness of plagiocephaly and bring Cranial Technologies’ outstanding products and top-rated care to growing families.”

Debbie James, CEO of Cranial Technologies, said:

“Since Cranial Technologies was founded over 30 years ago, our mission has been to provide the best possible treatment, experience and outcome for every family who seeks our care. We are excited to work with Eurazeo, a partner not only with an impressive track record in scaling companies, but one who believes in our mission alongside our team. Together, we look forward to welcoming new families around the world to our clinics. ”

EURAZEO'S DEEP HEALTHCARE EXPERTISE PROVIDES LAUNCHPAD FOR INTERNATIONAL GROWTH

With over 12% of private equity assets under management invested in the Healthcare sector, Eurazeo provides deep industry expertise alongside financial and human capital to help medium-sized Healthcare companies realize their growth potential.

Eurazeo's Healthcare portfolio includes, in particular, DORC, a leading producer of ophthalmic surgery instruments and equipment, and Peters Surgical, manufacturer of single-use sterilized surgical devices, in addition to multiple Digital Health and Biotech companies, all pursuing increased digitization and global expansion in partnership with Eurazeo.

In addition, Eurazeo holds a majority stake in Kurma Partners, a French venture capital firm specializing in biotechnology and medical innovation, and manages the Nov Santé fund on behalf of the French Insurance Federation (FFA) and Caisse des Dépôts, created to accelerate the digitization of the French healthcare industry.

ABOUT EURAZEO

- Eurazeo is a leading global investment company, with a diversified portfolio of €27 billion in assets under management, including nearly €19.2 billion from third parties, invested in 450 companies. With its considerable private equity, venture capital, private debt as well as real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 300 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.
- Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, Singapore, London, Luxembourg, Frankfurt, Berlin, Milan and Madrid.
- Eurazeo is listed on Euronext Paris.
- ISIN: FR0000121121 - Bloomberg: RF FP - Reuters: EURA.PA

ABOUT CRANIAL TECHNOLOGIES

- Founded in 1986, Cranial Technologies has provided plagiocephaly treatment to over 300,000 babies in 80 U.S. treatment centers. Our mission is to provide the best possible treatment, experience and outcome for every family who seeks our care. Cranial Technologies invented the DOC Band®, the first FDA-cleared cranial orthotic, and the DSi® (Digital Surface Imaging) system. For more information, visit : www.cranialtech.com.

EURAZEO CONTACT

Virginie Christnacht
HEAD OF COMMUNICATIONS
vchristnacht@eurazeo.com
+33 (0)1 44 15 76 44

Pierre Bernardin
HEAD OF INVESTOR RELATIONS
pbernardin@eurazeo.com
+33 (0)1 44 15 16 76

PRESS CONTACT

Julia Fisher
EDELMAN
Julia.Fisher@edelman.com
+1 646 301 2968